Discovery and Characterization of Novel Non-Hydroxamate HDAC11 Inhibitors
International Journal of Molecular Sciences · 20.06.2025 · 26 (13) · 5950
DOI: 10.3390/ijms26135950 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.06.2025. Verfasst von Aleksandra Kopranovic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering and Biotechnologiy, Darmstadt University of Applied Sciences, Haardtring 100, 64295 Darmstadt, Germany. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Histone Deacetylases, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Darmstadt University of Applied Sciences.
Abstract (Originalsprache)
Histone deacetylase 11 (HDAC11), the sole member of class IV HDACs, has gained prominence due to its unique enzymatic profile and pathological relevance in cancer, neurodegenerative, inflammatory diseases, and metabolic disorders. However, only a limited number of selective HDAC11 inhibitors have been identified, and many of these contain a potentially mutagenic hydroxamic acid as a zinc-chelating motif. Consequently, there is an imperative to identify potent and selective non-hydroxamate HDAC11 inhibitors with improved physicochemical properties. In this study, we conducted an extensive experimental high-throughput screening of 10,281 structurally diverse compounds to identify novel HDAC11 inhibitors. Two promising candidates, caffeic acid phenethyl ester (CAPE) and compound 9SPC045H03, both lacking a hydroxamic acid warhead, were discovered, showing micromolar inhibitory potency (IC50 = 1.5 and 2.3 µM, respectively), fast and reversible binding, and remarkable isozyme selectivity. Molecular docking revealed distinct zinc-chelating mechanisms involving either carbonyl oxygen (CAPE) or pyridine nitrogen (9SPC045H03), in contrast to canonical hydroxamates. Both compounds are drug-like and exhibit favorable physicochemical and pharmacokinetic profiles, particularly beneficial water solubility and good adsorption, making them valuable starting points for further optimization. These findings open new avenues for the development of selective, non-hydroxamate HDAC11 inhibitors with potential therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering and Biotechnologiy, Darmstadt University of Applied Sciences, Haardtring 100, 64295 Darmstadt, Germany.
- European University of Technology, European Union, 64295 Darmstadt, Germany.
ORCID-Profile: Franz-Josef Meyer-Almes
Förderung
- Darmstadt University of Applied Sciences
Zitieren
APA
Kopranovic, A., & Meyer-Almes, F. J. (2025). Discovery and Characterization of Novel Non-Hydroxamate HDAC11 Inhibitors. International Journal of Molecular Sciences, 26(13), 5950. https://doi.org/10.3390/ijms26135950
Vancouver
Kopranovic A, Meyer-Almes FJ. Discovery and Characterization of Novel Non-Hydroxamate HDAC11 Inhibitors. International Journal of Molecular Sciences. 2025;26(13):5950. doi:10.3390/ijms26135950
BibTeX
@article{Kopranovic2025,
author = {Kopranovic, Aleksandra and Meyer-Almes, Franz-Josef},
title = {Discovery and Characterization of Novel Non-Hydroxamate HDAC11 Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {5950},
doi = {10.3390/ijms26135950}
}
EUVIMED